RANBAXY

Ranbaxy Laboratories Ltd has informed the Exchange vide notes to Accounts in the Unaudited Financial Results (Provisional) for the quarter ended March 31, 2009 (taken on record by the Board of Directors of the Company at its meeting held on April 24, 2009) that: "For the year ended 31st Dec'08, the auditors have qualified the report as follows : "As stated in Note 24(a) of Schedule 26 to the financial statement, the Company has paid Rs. 277.28 million as managerial remuneration to its directors, which is in excess of the limites under the Act. Had the Company accounted for the remuneration in

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated April 24, 2009, titled "Q1 2009 Global Sales at Rs.15,584 MN - Emerging Markets Steady Despite Adverse Economic and Monetary Conditions". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_pr_24042009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding the standalone Results for the quarter ended on 31-MAR-2009 as follows: Net Sales of Rs. 80222.1 lacs for quarter ending on 31-MAR-2009 against Rs. 98728.6 lacs for the quarter ending on 31-MAR-2008. Net Profit / (Loss) of Rs. (77777.8) lacs for the quarter ending on 31-MAR-2009 against Rs. 10342.2 lacs for the quarter ending on 31-MAR-2008.

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated March 31, 2009, titled "Ranbaxy to launch Daiichi Sankyo's innovative antihypertensive, Olvance, in India: First product from Daiichi Sankyo's portfolio to be introduced through Ranbaxy". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_31032009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated March 30, 2009, titled "Ranbaxy Gains Final Approval from USFDA for Topirimate Tablets- Fourth ANDA from Ranbaxy to be approved in the last two Months". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_30032009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange vide notes to Accounts in the Audited Accounts for the year ended December 31, 2008 (taken on record by the Board of Directors of the Company at its meeting held on March 27, 2009) that: "The Auditors have qualified the company's financial statements for the year under review to the effect that the Company has paid Rs. 277.28 million as managerial remuneration to its Directors, which is in excess of the limits under the Companies Act (Act). In their opinion, had the Company accounted for the remuneration in accordance with the Act, the Loss af

Ranbaxy Laboratories Ltd has informed the Exchange that the Board at its meeting held on March 27, 2009 has approved the following: "(1) Appointment of Mr. Percy Shroff as a Director (Independent) of the Company in the casual vacancy caused by the resignation of Mr. Harpal Singh. Mr. Shroff has over 20 years experience in the medical field in Japan and India. He established the India offices and business operations for the Swedish multinational Elekta AB.. Mr. Shroff is Managing Director - India Head of Elekta Medical Systems India Pvt. Ltd., Gurgaon which is in the business of sales, servicin

Ranbaxy Laboratories Ltd has informed the Exchange that the Board at its meeting held on March 27, 2009 has approved the following: (1) Annual General Meeting (AGM) has been fixed for May 29, 2009. (2) Share transfer books for the purpose of AGM will remain closed from May 22, 2009 to May 29, 2009 (both days inclusive).

Ranbaxy Laboratories Ltd has informed the Exchange that the Board at its meeting held on March 27, 2009 has approved the Audited Accounts for the year ended December 31, 2008. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_BM_27032009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated March 25, 2009, titled "TGA- Australia Grants Approval for OZIDAL Risperidone Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_25032009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated March 23, 2009, titled "Ranbaxy's Paonta Sahib plant receives MHRA, UK and TGA, Australia Approvals for GMP Compliance - MHRA approval will also apply to all product filings for the EU". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_23032009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated March 09, 2009, titled "Ranbaxy gains Final Approval from USFDA for Ramipril Capsules; Third ANDA from Ranbaxy to be approved in the last two months". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_09032009.ZIP target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated March 06, 2009, titled "Ranbaxy gets TGA-Australia approval for SEBIFIN Terbinafine Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_PR_06032009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated March 05, 2009, titled "Ranbaxy secures USFDA approval for Quinapril+HCTZ Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_05032009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange that "Ranbaxy has just received a letter and information indicating that all pending and approved ANDAs from Ranbaxy's Paonta Sahib facility have been added to a list maintained under a policy entitled "Application Integrity Policy" or "AIP". Ranbaxy will analyze the letter and other information fully and respond appropriately in a timely manner". Further, a copy of the press statement dated February 26, 2009 shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Co

Ranbaxy Laboratories Ltd has informed the Exchange vide notes to Accounts in the Unaudited Financial Results for the three months and year ended December 31, 2008 (taken on record by the Board of Directors of the Company at its meeting held on January 22, 2009) that: "The Company received a sum of Rs. 35,848.78 Million during the quarter consequent to the allotment of equity shares and warrants on preferential basis to Daiichi Sankyo Company Limited, Japan. These proceeds have been utilized in line with the objects of the preferential issue, towards repayment of borrowings Rs. 24,876.05 Mill

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated January 22, 2009, titled "FY 2008 Global Sales at Rs.72,507 MN (+8%); Q4 2008 Global Sales at Rs.19,096 MN (+6%) - Emerging Markets Deliver Consistent Growth of 9% During the year; Developed Markets Grow 7% - Landmark Alliance with Daiichi Sankyo Completed; Company Receives Rs.35849 MN; Positioned for Stronger Growth". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a

Ranbaxy Laboratories Ltd has informed the Exchange regarding the standalone Results for the quarter ended on 31-DEC-2008 as follows: Net Sales of Rs. 95460.5 lacs for quarter ending on 31-DEC-2008 against Rs. 99332 lacs for the quarter ending on 31-DEC-2007. Net Profit / (Loss) of Rs. (80655.4) lacs for the quarter ending on 31-DEC-2008 against Rs. 4840 lacs for the quarter ending on 31-DEC-2007.

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated January 09, 2009, titled "Ranbaxy's Drug Discovery Team achieves significant landmark in GSK Research Collaboration; Starts Phase I Clinical Studies for Respiratory Inflammation Program". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_09012009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding outcome of the meeting of Board of Directors of the Company held on December 19, 2008. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_appointmentresig_19122008.ZIP target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated December 19, 2008, titled "Ranbaxy Reconstitutes Board of Directors following Strategic Alliance with Japan's Daiichi Sankyo - Ranbaxy CEO and Managing Director Malvinder Mohan Singh Takes Additional Role as Chairman of the Ranbaxy Board". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_19122008.ZIP target=NEW> For more details cl

Ranbaxy Laboratories Ltd has informed the Exchange that Mr. Surendra Daulet-Singh has resigned from the directorship of the Company with effect from December 15, 2008.

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated December 03, 2008, titled "Ranbaxy to market USFDA approved drug, for treatment of brain tumor, in India- Signs exclusive Licensing agreement with BioPro Pharmaceutical, Inc., USA". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_03122008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange that the auditor's have conducted the limited review of the unaudited financial results for the quarter ended September 30, 2008. A copy of the Limited Review report shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). <a href=/content/corporate/Ranbaxy_LR_01122008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd had informed the Exchange that M/s Daiichi Sankyo Company, Limited ("Daiichi Sankyo") having its registered office at 3-5-1 Nihonbashi-honcho, chuo-ku, Tokyo-103-8426, Japan, had acquired 220,690,423 Equity shares constituting 52.5% of the issued, Subscribed and Fully paid - up Equity Share Capital of Ranbaxy Laboratories Limited ("the Company"). The Company has now informed the Exchange that: "Daiichi Sankyo has acquired 48,020,900 Equity Shares of the Company today (i.e. November 7, 2008) from Mr. Malvinder Mohan Singh & Mr. Shivinder Mohan Singh, including their re

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated November 07, 2008, titled "Ranbaxy and Daiichi Sankyo Successfully Complete Landmark Deal". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_07112008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd had submitted to the Exchange a copy of "Notice of Change of Control" issued by the Company to the Trustees of Foreign Currency Convertible Bondholders. The Company has now informed the Exchange that: "Further to above, the RBI vide letter dated November 3, 2008 has rejected the application of the Company for early redemption of the Bonds. The Company has issued a communication dated November 4, 2008 to the Trustees of the Bondholders informing about the response of the RBI." The details of the same shall be available on the NSE website (http://www.nseindia.com) under:

Ranbaxy Laboratories Ltd has informed the Exchange that the Board of Directors of the Company in its meeting held on October 31, 2008 took note of the resignation of Mr. Nimesh N. Kampani from the directorship of the Company w.e.f. November 3, 2008.

Ranbaxy Laboratories Ltd has informed the Exchange regarding the press release dated October 31, 2008, titled "Q3 2008 Global Sales at Rs.18,884 MN (+14%); Emerging Markets Deliver Strong Growth of 20%; Developed Markets Grow by 9%". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). <a href=/content/corporate/Ranbaxy_PR_31102008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding the standalone Results for the quarter ended on 30-SEP-2008 as follows: Net Sales of Rs. 114629.5 lacs for quarter ending on 30-SEP-2008 against Rs. 103812 lacs for the quarter ending on 30-SEP-2007. Net Profit / (Loss) of Rs. (35293) lacs for the quarter ending on 30-SEP-2008 against Rs. 16816 lacs for the quarter ending on 30-SEP-2007.

Ranbaxy Laboratories Ltd has submitted to the Exchange a copy of the "Notice of Change of Control" issued by the Company on October 24, 2008 to the Trustees of the Foreign Currency Convertible Bond holders in terms of the Offering Circular of the Bonds. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_Up_27102008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange that the Committee of Directors at its meeting held today (i.e. October 20, 2008) has approved allotment of Equity Shares and Warrants on preferential basis to Daiichi Sankyo Company Limited, having its Registered Office at 3-5-1 Nihonbashi-honcho, Chuo-ku , Tokyo-103-8426, Japan as per details give below: (a) 46,258,063 fully paid Equity Shares of Rs.5 each at a premium of Rs.732 per share subject to lock-in period of three years from the date of allotment. The said Equity Shares will rank pari-passu in all respects with the existing Equity S

Ranbaxy Laboratories Ltd has informed the Exchange that M/s Daiichi Sankyo Company, Limited ("Daiichi Sankyo") having its Registered office at 3-5-1 Nihonbashi-honcho, Chuo-ku, Tokyo-103-8426, Japan, has acquired 52.5% of the Issued, Subscribed and Fully Paid-up Equity Shares of Rs.5 each ("Shares") of Ranbaxy Laboratories Limited ("the Company") comprising 220,690,423 shares. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ran

Ranbaxy Laboratories Ltd has informed the Exchange regarding the press release dated October 20, 2008, titled "Ranbaxy and Daiichi Sankyo Move Forward Toward The Completion of the Landmark Deal". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxylab_PR_20102008.zip target=NEW> For more details click here.</a>

Life Insurance Corporation of India has informed the Exchange that : "As per the guideline on Institutional Transactions in shares issued by Govt. of India during the year 1990, we hereby inform that Life Insurance Corporation of India has sold 25840113 equity shares face value of Rs. 5/- each of Ranbaxy Laboratories Ltd. @ Rs. 737/- per share (vide open offer)".

ICICI Securities Limited has submitted to the Exchange a copy of the Post Offer Public Announcement for the open offer by Daiichi Sankyo Company Limited for acquisition of up to 20% of emerging voting capital of Ranbaxy Laboratories Limited ("Offer"), released on October 17, 2008 in the newspapers. A copy of the Post offer Public announcement shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_POPA_17102008.zip target=NEW> For more details click h

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated October 16, 2008, titled "Ranbaxy achieves a significant landmark in Anti-Malarial Research; Obtains approval from DCGI to conduct Phase III Clinical Trial for its anti-malarial combination drug". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_17102008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange that: "The ESOPs Allotment Committee of Directors meeting held today i.e. October 13, 2008 has allotted 41,902 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 374111690 Equity Shares of Rs.5 each aggregating Rs.1870558450."

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated October 13, 2008, titled "Ranbaxy achieves another significant Milestone in GSK Research Collaboration; Submits IND application to DCGI for Respiratory Inflammation Candidate". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_13102008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange that: "The U.S. Department of Justice has now been provided with a comprehensive set of audit documents based on instructions by Ranbaxy Laboratories Limited, which will help resolve the questions raised by the U.S. government about the company's business practices and standards. Ranbaxy remains confident that its Pharmaceutical products are safe and effective and remains committed to cooperatively working with all regulatory and legislative authorities".

ICICI Securities Limited has informed the Exchange that pursuant to the SEBI (Substantial Acquisition of shares and takeovers) Regulations, 1997 and subsequent amendments thereto, Daiichi Sankyo Company Limited (referred to as the "Acquirer") is making an offer to the public shareholders of Ranbaxy Laboratories Limited ("RLL"), to acquire up to 92,519,126 fully paid-up equity shares of RLL, representing 20% of the emerging voting capital of RLL at a price of Rs. 737 per equity share, payable in cash (referred to as the "Offer"). ICICI securities Limited is acting as the Manager to the offer.

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated September 18, 2008, titled " Ranbaxy Laboratories Ltd., Retains former New York city Mayor Rudy Giuliani to lead team in resolution of issues raised by U.S. Food & Drug Administration". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_18092008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has submitted to the Exchange a copy of 'Ranbaxy, Statement on FDA Letters'. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_Updates_17092008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange that the auditor's have conducted the limited review of the unaudited financial results for the quarter ended June 30, 2008. A copy of the Limited Review report alongwith explanation on the observations of the Auditors shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). <a href=/content/corporate/Ranbaxy_LR_08092008.zip target=NEW> For more details click here.</a>

ICICI Securities Limited has informed the Exchange with reference to the Public Offer for acquisition of 20% of Emerging Voting Capital of Ranbaxy Laboratories Limited by Daiichi Sankyo Company, Limited - Pursuant to Regulations 10 and 12 of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 1997 and subsequent amendments thereto, that: ICICI Securities Ltd, as Manager to the above Public Offer, would like to bring to the notice of all concerned that as per the corrigendum published in the newspaper on August 11, 2008, the Letter of Offer has

ICICI Securities Limited has informed the Exchange regarding the Public Announcement published on June 16, 2008 ('PA') published in the newspaper. As per the PA, pursuant to the SEBI (Substantial Acquisition of Shares and Takeovers), Regulations, 1997, as amended ('the Regulations'), Daiichi Sankyo Company Limited ('Acquirer') had announced making an offer to the public shareholders of Ranbaxy Laboratories Limited ('RLL'), to acquire up to 92,519,126 fully paid-up equity shares of RLL, representing 20% of the emerging voting capital of RLL at a price of Rs. 737 per equity share of face value o

ICICI Securities Limited has informed the Exchange regarding Public Offer for acquisition of 20% of Emerging Voting Capital of Ranbaxy Laboratories Limited by Daiichi Sankyo Company, Limited - Pursuant to Regulations 10 and 12 of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 1997 and subsequentamendments thereto. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PO_0

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated August 01, 2008, titled "Ranbaxy's ARV Drug, Abacavir 300MG Tablets ,Included in WHO's Pre-Qualification List; Company Now Has a Total of 18 ARVS in the WHO Program; Ranbaxy Committed to Support the Global Fight Against HIV/AIDS". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_Pr_01082008.zip target=NEW> For more details click her

Icici Securities Limited has informed the Exchange regarding Open Offer by Daiichi Sankyo Company Limited for acquisition of up 20% of emerging voting capital of Ranbaxy Laboratories Limited ("Offer"). The details of the same are as follows: "As Manager to the Offer, pursuant to Regulation 18(1) of the Regulation , the draft Letter of Offer has been submitted to Securities and Exhange Board of India ("SEBI") on June 27, 2008 on which observations in terms of Regulation 18(2) of the Regulations are being awaited. In term of the subject PA the last date for dispatch of the Letter of Offer was J

Ranbaxy Laboratories Ltd has informed the Exchange that at the Extra-ordinary General Meeting held on July 15, 2008, the shareholders passed a Special Resolution for amendment in the existing Employees Stock Option Scheme of the Company to the effect that maximum number of stock options that may be granted to individual management employee in a year be increased from 40,000 to 3,00,000. Further, the Company has submitted to the Exchange a copy of the special resolution (alongwith Explanatory Statement) passed in the Extra- Ordinary General Meeting held on July 15, 2008. The copy of the same sh